.Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A10B_BloodGlucoseLoweringDrugsExclInsulins.A10BB12_Glimepiride.Glimepiride .Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A10B_BloodGlucoseLoweringDrugsExclInsulins.A10BB12_Glimepiride.Glimepiride| name: | Glimepiride |
| ATC code: | A10BB12 | route: | oral |
| n-compartments | 2 |
Glimepiride is a second-generation sulfonylurea antidiabetic drug used for the treatment of type 2 diabetes mellitus. It stimulates pancreatic beta cells to release insulin, thereby lowering blood glucose levels. Glimepiride is approved and widely used in clinical practice today.
Pharmacokinetic parameters reported in healthy adult volunteers (both sexes), oral administration, single 2 mg dose.
Cho, HJ, et al., & Kim, HG (2011). Effect of genetic polymorphisms on the pharmacokinetics and efficacy of glimepiride in a Korean population. Clinica chimica acta; international journal of clinical chemistry 412(19-20) 1831–1834. DOI:10.1016/j.cca.2011.06.014 PUBMED:https://pubmed.ncbi.nlm.nih.gov/21704609
Lee, HW, et al., & Yoon, YR (2012). Frequency of CYP2C9 variant alleles, including CYP2C9*13 in a Korean population and effect on glimepiride pharmacokinetics. Journal of clinical pharmacy and therapeutics 37(1) 105–111. DOI:10.1111/j.1365-2710.2010.01238.x PUBMED:https://pubmed.ncbi.nlm.nih.gov/21208246
Kirchheiner, J, et al., & Brockmöller, J (2005). Effect of genetic polymorphisms in cytochrome p450 (CYP) 2C9 and CYP2C8 on the pharmacokinetics of oral antidiabetic drugs: clinical relevance. Clinical pharmacokinetics 44(12) 1209–1225. DOI:10.2165/00003088-200544120-00002 PUBMED:https://pubmed.ncbi.nlm.nih.gov/16372821